Skip to main content

Table 1 Model transition probabilities [30]

From: Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

 DTG + TDF/3TCEFV + TDF/3TCaLPV/r + TDF/3TCb
Virology suppression
 First 11 months16.3%a/15.1%b12.4%10.4%
 Month 12–220.2%0.1%0.1%
 After month 220.0%0.0%0.0%
Discontinuation due to failure (first line)
 First 11 months0.46%a/0.17%b0.86%0.60%
 Month 12–220.10%a/0.05%b0.08%0.04%
 After month 220.05%a/0.02%b0.06%0.04%
Discontinuation with other cause (first line)
 First 11 months0.55%a/0.63%b0.62%0.91%
 Month 12–220.12%a/0.18%b0.06%0.06%
 After month 220.06%a/0.08%b0.04%0.06%
Discontinuation (second line plus)
 First 11 months1.03%1.54%1.54%
 Month 12–220.23%0.10%0.10%
 After month 220.10%0.10%0.10%
CD4+ increase
 First 11 months20.2916.4215.46
 Month 12–222.510.560.56
 After month 22− 2.32− 2.32− 2.32
  1. aTreatment-naïve setting
  2. bFirst-line failure setting